Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Elenestinib, an Investigational, Next Generation KIT D816V Inhibitor, Reduces Mast Cell Burden, Improves Symptoms, and Has a Favorable Safety Profile in Patients with Indolent Systemic Mastocytosis: Analysis of the Harbor Trial

Blood (2023) 142 (Supplement 1): 76.

https://doi.org/10.1182/blood-2023-188904

Published: 2023

Journal Articles

Prediction of Relapse after Allogeneic Stem Cell Transplantation Using Individualized Minimal Residual Markers; The Prospective Nordic Study NMDSG14B

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-138782

Published: 2020

Journal Articles

Pure Red Cell Aplasia - a New Manifestation of CTLA4 Mutation

Ingunn Dybedal, MDPhD, Anna Mari Lone, PhD, Hanne Sørmo Sorte, MSc, Lorant Farkas, MD PhD, Jürgen Rolke, MD, Robert Brudevold, MD, Asbjørg Stray-Pedersen, MD PhD, Kjetil Tasken, MD PhD

Blood (2015) 126 (23): 2225.

https://doi.org/10.1182/blood.V126.23.2225.2225

Published: 2015

Journal Articles

Characterisation of the Stem and Progenitor Cell Hierarchy in Patients with CMML

Onima Chowdhury, MD PhD, Petter S Woll, PhD, Una Kjällquist, PhD, Helen Doolittle, MD, Rikard Erlandsson, PhD, Kristina Anderson, MD PhD, Ingunn Dybedal, MD PhD, Adam Mead, MDPhD, Sally-Ann Clark, PhD, Mette S. Holm, MD PhD, Peter Hokland, MD DMSc, Lars Nilsson, MD PhD, Sten Linnarsson, PhD, Eva Hellstrom-Lindberg, MD PhD, Sten Eirik W Jacobsen, MD PhD

Blood (2014) 124 (21): 1896.

https://doi.org/10.1182/blood.V124.21.1896.1896

Published: 2014

Journal Articles

Diverse Genetic Lesions In Myelodysplastic Syndromes Originate Exclusively In Rare MDS Stem Cells

Blood (2013) 122 (21): 4195.

https://doi.org/10.1182/blood.V122.21.4195.4195

Published: 2013

Journal Articles

Evaluation of Azacitidine in Transfusion-Dependent, Epo-Refractory Patients with Lower-Risk Myelodysplastic Syndrome,

Magnus Tobiasson, MD, Lena Brandefors, MD, Ingunn Dybedal, MD, PhD, Hege Garelius, MD, Michael Grövdal, MD, PhD, Inge Hoegh Dufva, MD, PhD, Lars Kjeldsen, MD, PhD, Lars Nilsson, MD, PhD, Astrid Olsnes Kittang, MD, PhD, Anna Porwit, MD, PhD, Leonie Saft, MD, Mette Skov Holm, MD, PhD, Lars Möllgård, MD, Phd, Eva Hellström-Lindberg

Blood (2011) 118 (21): 3798.

https://doi.org/10.1182/blood.V118.21.3798.3798

Published: 2011

Journal Articles

Favorable Therapeutic Responses in Newly Diagnosed CML-CP Patients Induced by Dasatinib Are Reflected At the CD34+CD38+ Progenitor Cell but Not At the CD34+CD38− Stem Cell Level: Results From Randomized NordCML006 Study

Blood (2011) 118 (21): 784.

https://doi.org/10.1182/blood.V118.21.784.784

Published: 2011

Journal Articles

The Proportion of Ph+ CD34 + CD38 neg Leukemic Stem Cells In the Bone Marrow of Newly Diagnosed Patients with Chronic Myeloid Leukemia (CML) In Chronic Phase (CP) Is Variable and Correlates with High Sokal Risk, High Leukocyte Count, Low Hemoglobin Concentration, Splenomegaly and Increased Hematological Toxicity During Initial TKI-Therapy. Data From a Randomized Phase II NordCML006 Study

Blood (2010) 116 (21): 667.

https://doi.org/10.1182/blood.V116.21.667.667

Published: 2010

Journal Articles

Lenalidomide in High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia with Chromosome 5 Abnormalities.

Lars Möllgård, Lars Nilsson, Lars Kjeldsen, Ingunn Dybedal, Inge Hogh Dufva, Hege Garelius, Jan Maxwell Norgaard, Olle Linder, Elisabeth Ejerblad, Jan Astermark, Eva Hellström-Lindberg

Blood (2009) 114 (22): 115.

https://doi.org/10.1182/blood.V114.22.115.115

Published: 2009

Journal Articles

Clonal Expansion of T/NK-Cells during Tyrosine Kinase Inhibitor Dasatinib Therapy

Blood (2008) 112 (11): 573.

https://doi.org/10.1182/blood.V112.11.573.573

Published: 2008

Journal Articles

Treatment with Erythropoietin and G-CSF Improves Survival in MDS Patients with Low Transfusion Need.

Martin Jädersten, MD, Luca Malcovati, MD, Ingunn Dybedal, MD, Matteo Giovanni Della Porta, MD, Rosangela Invernizzi, MD, Scott M. Montgomery, PhD, Cristiana Pascutto, Anna Porwit-MacDonald, MD, Mario Cazzola, MD, Eva Hellström-Lindberg, MD, PhD

Blood (2006) 108 (11): 521.

https://doi.org/10.1182/blood.V108.11.521.521

Published: 2006

Journal Articles

Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF

Martin Jädersten, Scott M. Montgomery, Ingunn Dybedal, Anna Porwit-MacDonald, Eva Hellström-Lindberg

Blood (2005) 106 (3): 803–811.

https://doi.org/10.1182/blood-2004-10-3872

Published: 2005

Journal Articles

Human reconstituting hematopoietic stem cells up-regulate Fas expression upon active cell cycling but remain resistant to Fas-induced suppression

Ingunn Dybedal, Liping Yang, David Bryder, Ingbritt Aastrand-Grundstrom, Karin Leandersson, Sten Eirik W. Jacobsen

Blood (2003) 102 (1): 118–126.

https://doi.org/10.1182/blood-2002-07-2286

Published: 2003

Journal Articles

Tumor necrosis factor (TNF)–mediated activation of the p55 TNF receptor negatively regulates maintenance of cycling reconstituting human hematopoietic stem cells

Ingunn Dybedal, David Bryder, Anna Fossum, Leiv S. Rusten, Sten Eirik W. Jacobsen

Blood (2001) 98 (6): 1782–1791.

https://doi.org/10.1182/blood.V98.6.1782

Published: 2001

Journal Articles

Treatment of Anemia in Myelodysplastic Syndromes With Granulocyte Colony-Stimulating Factor Plus Erythropoietin: Results From a Randomized Phase II Study and Long-Term Follow-Up of 71 Patients

Eva Hellström-Lindberg, Tomas Ahlgren, Yves Beguin, Magnus Carlsson, Jan Carneskog, Inger Marie Dahl, Ingunn Dybedal, Gunnar Grimfors, Lena Kanter-Lewensohn, Olle Linder, Michaela Luthman, Eva Löfvenberg, Herman Nilsson-Ehle, Jan Samuelsson, Jon-Magnus Tangen, Ingemar Winqvist, Gunnar Öberg, Anders Österborg, Åke Öst

Blood (1998) 92 (1): 68–75.

https://doi.org/10.1182/blood.V92.1.68.413k23_68_75

Published: 1998

Journal Articles

Transforming Growth Factor-β 1 Abrogates Fas-Induced Growth Suppression and Apoptosis of Murine Bone Marrow Progenitor Cells

Ingunn Dybedal, Fengan Guan, Ole Johan Borge, Ole Petter Veiby, Veslemøy Ramsfjell, Shigekazu Nagata, Sten Eirik W. Jacobsen

Blood (1997) 90 (9): 3395–3403.

https://doi.org/10.1182/blood.V90.9.3395

Published: 1997

NARROW

Elenestinib, an Investigational, Next Generation KIT D816V Inhibitor, Reduces Mast Cell Burden, Improves Symptoms, and Has a Favorable Safety Profile in Patients with Indolent Systemic Mastocytosis: Analysis of the Harbor Trial

Prediction of Relapse after Allogeneic Stem Cell Transplantation Using Individualized Minimal Residual Markers; The Prospective Nordic Study NMDSG14B

Pure Red Cell Aplasia - a New Manifestation of CTLA4 Mutation

Characterisation of the Stem and Progenitor Cell Hierarchy in Patients with CMML

Diverse Genetic Lesions In Myelodysplastic Syndromes Originate Exclusively In Rare MDS Stem Cells

Evaluation of Azacitidine in Transfusion-Dependent, Epo-Refractory Patients with Lower-Risk Myelodysplastic Syndrome,

Favorable Therapeutic Responses in Newly Diagnosed CML-CP Patients Induced by Dasatinib Are Reflected At the CD34+CD38+ Progenitor Cell but Not At the CD34+CD38− Stem Cell Level: Results From Randomized NordCML006 Study

Lenalidomide in High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia with Chromosome 5 Abnormalities.

Clonal Expansion of T/NK-Cells during Tyrosine Kinase Inhibitor Dasatinib Therapy

Treatment with Erythropoietin and G-CSF Improves Survival in MDS Patients with Low Transfusion Need.

Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF

Human reconstituting hematopoietic stem cells up-regulate Fas expression upon active cell cycling but remain resistant to Fas-induced suppression

Tumor necrosis factor (TNF)–mediated activation of the p55 TNF receptor negatively regulates maintenance of cycling reconstituting human hematopoietic stem cells

Treatment of Anemia in Myelodysplastic Syndromes With Granulocyte Colony-Stimulating Factor Plus Erythropoietin: Results From a Randomized Phase II Study and Long-Term Follow-Up of 71 Patients

Transforming Growth Factor-β 1 Abrogates Fas-Induced Growth Suppression and Apoptosis of Murine Bone Marrow Progenitor Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only